Antimicrobial Defined Daily Dose in Neonatal Population: Validation in the Clinical Practice.

Background: Currently, there is no validated method for estimating antimicrobial consumption in the neonatal population, as it exists for adults using Defined Daily Doses (DDD). In neonatology, although there are different methods, each one with advantages and disadvantages, there is no unified criterion for use. The aim of this study is to validate the neonatal DDD designed as a new standardised form of antimicrobial consumption over this population.

Antimicrobial defined daily dose in neonatal population.

Background: Antimicrobial defined daily dose (DDD), a standardized metric to assess antimicrobial consumption in adult population, has limitations hampering its use in neonatal patients. This study proposes an alternative DDD design applicable for neonates.

Methods: Neonates (<1 month-old) from 6 Spanish hospitals during a 12-months period were included.

Antimicrobial defined daily dose in neonatal population.

Background: Antimicrobial defined daily dose (DDD), a standardized metric to assess antimicrobial consumption in adult population, has limitations hampering its use in neonatal patients. This study proposes an alternative DDD design applicable for neonates.

Methods: Neonates (<1 month-old) from 6 Spanish hospitals during a 12-months period were included.

Nadolol for the treatment of infantile hemangioma.

Purpose: The successful use of nadolol as an alternative to propranolol therapy in three cases of infantile hemangioma is reported.

Summary: Infantile hemangioma is a benign vascular neoplastic disorder that affects up to 10% of newborns and can lead to deformity or local complications in severe cases. Propranolol, administered alone or in combination with corticosteroids, is increasingly used to treat infantile hemangioma, but its ability to cross the blood-brain barrier and potentially cause central nervous system adverse effects has prompted research on alternative β-blocker therapies for the disorder that have more favorable safety profiles, including nadolol.